ABSTRACT: Excess nitric oxide (NO) produced by neuronal nitric oxide synthase (nNOS) is implicated in neurodegenerative disorders. As a result, inhibition of nNOS and reduction of NO levels is desirable therapeutically, but many nNOS inhibitors are poorly bioavailable. Promising members of our previously reported 2-aminoquinoline class of nNOS inhibitors, although orally bioavailable and brain-penetrant, suffer from unfavorable off-target binding to other CNS receptors, and they resemble known promiscuous binders. Rearranged phenyl ether-and aniline-linked 2-aminoquinoline derivatives were therefore designed to (a) disrupt the promiscuous binding pharmacophore and diminish off-target interactions and (b) preserve potency, isoform selectivity, and cell permeability. A series of these compounds was synthesized and tested against purified nNOS, endothelial NOS (eNOS), and inducible NOS (iNOS) enzymes. One compound, 20, displayed high potency, selectivity, and good human nNOS inhibition, and retained some permeability in a Caco-2 assay. Most promisingly, CNS receptor counterscreening revealed that this rearranged scaffold significantly reduces off-target binding.
■ INTRODUCTION
Neurodegenerative disorders, such as Alzheimer's, Parkinson's, and Huntington's diseases, amyotrophic lateral sclerosis (ALS), and others, are diseases where the structure and function of neurons gradually deteriorate, leading to the motor, cognitive, and psychological difficulties associated with these disorders. Neuronal damage also occurs in head trauma, cerebral palsy, stroke, and ischemic events. With the world's increasingly aged population, the incidence of neurodegenerative disorders is also increasing, and, with most treatments limited to palliative care, the development of new therapeutics is of utmost importance.
A target receiving considerable attention is neuronal nitric oxide synthase (nNOS). 1 Nitric oxide (NO), an important second messenger, is produced by three nitric oxide synthase (NOS) enzymes: inducible nitric oxide synthase (iNOS), required for immune response activation, endothelial nitric oxide synthase (eNOS), which regulates blood pressure and vascular tone, and nNOS, necessary for neuronal signaling. 2 If nNOS is overexpressed or overactive in neuronal tissue, however, the excess NO, especially if converted to peroxynitrite, can cause free radical damage to cellular structures and protein nitration, which can lead to misfolding and aggregation. 3, 4 Abnormally high levels of nNOS and NO have therefore been associated with or implicated in numerous neurodegenerative disorders, 5−8 making nNOS inhibition a desirable therapeutic avenue for the treatment or prevention of these conditions. 9−11 Nitric oxide synthases are unique among mammalian enzymes in that they are homodimers requiring five cofactors to function: flavin adenine dinucleotide (FAD), flavin mononucleotide (FMN), and reduced nicotinamide adenine dinucleotide phosphate (NADPH), found in each monomer's reductase domain, and (6R)-5,6,7,8-tetrahydrobiopterin (H 4 B) and the final electron acceptor, heme, which bind in each monomer's oxygenase domain along with the substrate, Larginine. Between the two domains lies a flexible region where calmodulin binds when activated by calcium ion, and electron flow proceeds from one monomer's reductase domain to the other's oxygenase domain, 12 where NO is produced as Larginine is oxidized to L-citrulline. 13 One important challenge in the design of nNOS inhibitors is that eNOS and iNOS, in sequence and overall structure, are nearly identical to nNOS, especially in their active site residues. 14, 15 Nonselective NOS inhibition is potentially dangerous: iNOS inhibition could interfere with immune activation, while eNOS inhibition can cause severe hypertension and other cardiovascular liabilities. 16 Additionally, many nNOS inhibitors are mimics of L-arginine and thus have high basicity and polarity, large total polar surface area (tPSA), and many hydrogen bond donors, all of which hinder the inhibitors' blood−brain barrier (BBB) penetration and diminish therapeutic use. 17 In 2014, we reported a series of 2-aminoquinolines as competitive nNOS inhibitors. 18 Two compounds, 1 and 2 ( Figure 1 ), were considered promising candidates for further development because of their high potency and selectivity over iNOS and eNOS. These compounds are permeable in a Caco-2 assay, and 1 displayed good oral bioavailability and brain permeation in mice. Although only modestly potent in vivo, 2 also inhibited nNOS in rat brain homogenates and in the brains of live rats. Despite their promise, 1 and 2 have major disadvantages. Compound 2 has a poor safety profile in rats, displaying toxic side effects at the doses required for effective nNOS inhibition. Furthermore, a counterscreen against a panel of relevant CNS targets and receptors performed by the Psychoactive Drug Screening Program (PDSP) 19 revealed that 1 and especially 2 are promiscuous binders with strong (<100 nM) affinities for serotonin, opioid, and histamine receptors, as well as for the dopamine and norepinephrine transporters, which could cause unfavorable side effects. Additionally, compounds 1 and 2 are quite time-consuming to synthesize (12 steps) . Because of these problems, we chose to investigate alternative aminoquinoline-containing scaffolds for nNOS inhibition.
Interestingly, the literature revealed that compounds such as ketanserin, haloperidol, and risperidone, which also bind to multiple, similar CNS targets, have overall structural motifs in common with 1 and 2: two hydrophobic or aromatic exteriors (one, often halogenated), joined by an interior alkylamine linker, a pharmacophore ( Figure 2A ) that appears to "stick" to GPCRs and other CNS targets. 20 Lowe and colleagues at Pfizer 21 reported the structure of 3, a potent nNOS inhibitor with very high affinity for dopamine and serotonin receptors. Removal of the exterior hydrophobic group diminished off-target binding, and when an exterior polar amine was attached to an interior hydrophobic group (such as in 4 and 5), higher potency and isoform selectivity resulted. 22, 23 Similar exterior polar amines (especially N-methyl and N,Ndimethylamines) were also effective in conferring potency and selectivity of NeurAxon's thiophenecarboximidamides. 24, 25 Design of an analogous "inverted" aminoquinoline-containing compound ( Figure 2B ) resulted in 6, with the halves of the molecule joined by a phenyl ether, the same as in 4 and 5. We hypothesized that in addition to reducing off-target binding, this structural rearrangement could have additional benefits. First, the external amine of 6 could potentially form interactions in various spots peripheral to the nNOS active site such as Asp597, the H 4 B site, or residues of the substrate access channel hydrophobic pocket, all of which have been shown to play significant roles in conferring potency or isoform selectivity. 26−28 Second, the predicted physicochemical properties of 6 are similar to those of 1 and 2 (CLogP: 2−4, <7 rotatable bonds, TPSA < 80 Å 2 , and <4 hydrogen-bond donors), making it plausible that the cellular permeability of 1 and 2 could be preserved.
In addition to 6, we designed and synthesized a small library of related compounds (7−12, Figure 3 ); all were assayed against purified rat nNOS, murine iNOS, and bovine eNOS. Encouraged by the potency and isoform selectivity of 8 and 9, different modifications were performed to optimize the structure and examine the SAR. First, 13 and 14 were synthesized to investigate if longer tail lengths could provide additional or enhanced beneficial contacts with the enzyme. Second, although 8 and 9 have the amine-containing moiety located meta to the phenyl ether, para-substituted compounds 15 and 16 were also prepared to investigate the role that different ring substitution patterns may play. Third, we reasoned that bioisosteric replacement of the phenyl ether with an aniline (17 and 18) might introduce another contact in the region near the heme propionates, resulting in greater affinity for nNOS.
Finally, we performed specific, structure-based optimizations to improve the potency and selectivity of lead 9. X-ray crystallography indicated that the center aryl rings of 8 and 9 abut two residues, Tyr706 and Asn569. We hypothesized that introduction of halogens para to the phenyl ether linkage, as in 19 and 20, could provide additional van der Waals interactions with Tyr706 or the surrounding hydrophobic structures. Likewise, by converting the phenyl ring to a pyridine (21), a hydrogen bond or polar contact could potentially form between the pyridine nitrogen and the side chain of Asn569. We also proposed that contacts might be made with other residues of the hydrophobic pocket (such as Met336 and Leu337) by placing a methyl group alpha to the exterior amine group of 9 (to yield 22). All compounds were assayed against purified rat nNOS, and select compounds were assayed against eNOS, iNOS, and human nNOS, for cellular permeability in a Caco-2 model, and against a panel of CNS targets in the PDSP to assess their off-target binding.
Chemistry. Previously, 7-substituted-2-aminoquinolines were prepared via readily accessible chloroquinoline 23 18, 29 (Scheme 1) by performing a Koŕodi amidation 30 to produce 2-acetamidoquinoline 25. Unfortunately, this procedure gives irreproducible yields and is not readily amenable to scale-up. Smith et al. 31 reported the palladium-catalyzed amination of 2-chloroquinolines using LHMDS as both an ammonia surrogate 
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Article and base; applying this procedure to 23 afforded 2-aminoquinoline 24 in nearly quantitative yield on a multigram scale. Treatment with N-acetylimidazole in refluxing THF afforded 25, and free-radical bromination (as previously reported) yielded versatile bromide 26.
The phenol and aniline halves were then prepared. To prepare 6 (Scheme 2A), 3-methoxyphenethylamine (27) was dimethylated, and the O-methyl group of 28 was removed to yield phenol 29. Monomethyl phenol 32 (needed for compound 7) was prepared from 3-methoxyphenethyl bromide (30, Scheme 2B) and methylamine, followed by demethylation of 31 and immediate Boc-protection (to aid in purification and prevent later interference by the free secondary amine). For the benzylic amine of 8, phenol 34 (Scheme 2C) was prepared by reductive amination of commercially available aldehyde 33 with N,N-dimethylamine. Similarly, exchanging N,N-dimethylamine for methylamine (needed for 9) yielded an amine, which was protected as 35. Phenol 37 (Scheme 2D) was prepared for the synthesis of 10 by Boc-protecting commercially available 36.
The longer linker of 13, via phenol 40, was prepared by a Sonogashira coupling of 3-iodophenol 38 with N,N-dimethylpropargylamine, followed by reduction of the triple bond of 39 to yield 40 (Scheme 3A). For compound 14, 42 was prepared by a Mitsunobu reaction between resorcinol 41 and N,Ndimethylethanolamine 32 (Scheme 3B). As performed for the meta-analogues, phenols 44 and 45 (for analogues 15 and 16, respectively, Scheme 4) were prepared from 4-hydroxybenzaldehyde (43) and either N,N-dimethylamine (for 44) or methylamine (for 45).
The anilines required for 17 and 18 were prepared from 3-nitrobenzyl bromide (46, Scheme 5) upon treatment with either dimethylamine (47) or methylamine (followed by Bocprotection to yield 49). Reduction of the nitro group with Raney nickel afforded 48 (for 17) and 50 (for 18).
Finally, the substituted phenols (for 19−22, Scheme 6A) could be prepared by employing the reductive amination/Boc protection protocol to commercially available aldehydes (51, 52) 
Article respectively. Lastly, the pyridinol 59 (for 21, Scheme 6B) was prepared by reductive amination of nicotinaldehyde 57 and cleavage of the methyl group of 58; Boc-protection furnished 59.
With the halves of the phenyl ether-substituted quinolines in hand, assembly of the final cores (Scheme 7) was completed by first treating the desired phenol [29, 32, 34, 35, 37, 40, 42, 44, 45, [54] [55] [56] 59 , or commercially available 3-hydroxypyridine or 3-(N,N-dimethylamino)phenol (for compounds 11 and 12, respectively)] with sodium hydride in DMF at 0°C. A solution of 26 was then added; the reaction was typically complete within 1 h. Yields were good but were lower for the tertiary amines because of partial solubility in the aqueous DMF solutions produced in the workup. The intermediate acetamides (60−74) were not characterized and were deprotected immediately after purification: the acetyl group was first removed by K 2 CO 3 in refluxing methanol, and after isolation, the free aminoquinolines were treated with methanolic HCl in ether to produce water-soluble hydrochloride salts. Compounds without a Boc group were isolated after 5−15 min; those with a Boc group were stirred overnight for deprotection. In the case of 72, HCl induced unfavorable side reactions, so TFA was used instead.
The microwave alkylation procedure of Romero et al. 33 was employed to synthesize aniline 18 (Scheme 7). Compound 26, excess 50, and catalytic potassium iodide were heated in acetonitrile under microwave irradiation to furnish intermediate 75, which was deprotected as described above. Unfortunately, because of its nucleophilic amine, 48 only produced watersoluble quaternization products upon reaction with 26. It was proposed that the two halves of N-linked compound 17 could be joined via reductive amination, beginning with the quinolinecarboxaldehyde 81. After many unsuccessful attempts to prepare 81 from 25 and 26, 81 was prepared in five steps 34 (Scheme 8), starting with a Wittig cyanovinylation of commercially available aldehyde 76; the desired trans-isomer 77 was obtained in good yield. Iron-catalyzed reductive cyclization yielded aminoquinoline 78, which was acetylated in good yield using N-acetylimidazole. Ester 79 was reduced to alcohol 80, and oxidation to 81 was performed using DessMartin periodinane. An indirect reductive amination with 48 was effective at elevated temperatures, and the crude acetamide was deprotected to yield 18.
■ RESULTS AND DISCUSSION
Compounds 6−22 were first assayed against purified rat nNOS, murine macrophage iNOS, and bovine eNOS using the hemoglobin capture assay. 35, 36 These species are used because (a) it is easiest to purify and readily obtain crystallographic data with these isozymes, and (b) there is a large active-site homology between mammalian species and therefore, while not 100% accurate, an adequate approximation of isoform selectivity can be obtained. Table 1 summarizes the apparent K i values and isoform selectivity values for 6−22; for the sake of comparison, values for 1 and 2 are included.
The first series of compounds, 6−12, is less potent than 1 or 2. At first glance, it appears that compounds with a basic amino group (6−10) are more potent against nNOS than those with less basic groups such as pyridine (11) and N,N-dimethylaniline, which rendered compound 12 essentially inactive. The positioning of the tail amino group plays a role in enzyme− inhibitor interactions. The crystal structures of nNOS-6 and nNOS-7 are compared side by side in Figure 4 . The strong 2-aminoquinoline-Glu592 (arginine mimic) interaction characteristic of this class is well supported by the strong electron density. In contrast, the central aryl ring and the tail regions show rather weak density, indicative of disordering. The methylamine of 7 reaches the H 4 B site because the tail is long enough to displace the water molecule normally present in this site, and H-bond either with H 4 B or with the nearby heme propionate ( Figure 4B ). This interaction pushes the central aryl ring into nonbonded contact with the Tyr706 side chain. However, the tertiary amino group of 6 does not interact with H 4 B or heme, but hangs adjacent to Met336 because the central aryl ring presses against the heme propionate ( Figure 4A ). The lack of both the H 4 B site and Tyr706 contacts likely explains why 6 is less potent than 7.
When the tail is one methylene shorter, (8 and 9 vs 6 and 7, respectively) the potency is also increased. As shown in Figure  5 , the tertiary amino group of 8 can form an H-bond with Asn569, while the secondary amino group of 9 is involved in a water-mediated H-bonding network with H 4 B and heme. The phenyl ring of 9 forms a pi-stacking interaction with Tyr706 (these rings are >4 Å apart in the nNOS-8 structure). These same interactions are observed in the nNOS-10 structure, which has a primary amino group, (see Supporting Information, Figure S1 ).
Two trends are clear. First, potency is increased slightly upon removal of one methyl group from the tertiary amines; 9 and 10 are more potent than 8, and 7 is more potent than 6. The 
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Article protonated secondary amino group bears two hydrogens and is a stronger H-bond donor than the tertiary amino group, as demonstrated by 7 and 9. Second, the longer chains of 6 and 7 show higher flexibility (structure disordering) in the phenyl ether and tail region when compared to that of 8 and 9 and thus could result in weaker or partial interactions as a result of entropy, leading to lower potency than that of 8 and 9. Interactions with Asn569 or the H 4 B site are crucial for the activity of these compounds; the short amino group of 12 is incapable of forming these interactions, and this could be why 12 has little activity.
Interestingly, the n/e selectivity for 8 and 9 is similar to that observed for 1 or 2. It is known that contact between the halophenyl rings of 1 and 2 and the hydrophobic pocket residues Tyr706, Leu337, and Met336 improves potency and n/e selectivity. 18 What is responsible for the n/e selectivity for these compounds lacking obvious hydrophobic contact? X-ray crystallography indicates that in eNOS, a common binding mode is observed for most phenyl ether-linked aminoquinolines, characterized by an "upward" position of the ether bond, where the phenyl ring sits perpendicular to the plane of the aminoquinoline. In the eNOS-9 structure (Figure 6A ), the 
Article perpendicular orientation of the phenyl ring breaks the pistacking interactions with Tyr706 (distance >6 Å), and the phenyl ring and methylamine portion can be modeled in alternate conformations where the amine can either face toward or away from the H 4 B site. Similar upward phenyl ring positions are also observed for 7 and 8 bound to eNOS (see Figure S2 ), indicating that this position occurs regardless of tail length or amine alkylation pattern.
While the perpendicular orientations found in these eNOS structures would diminish many of the interactions that confer binding to nNOS (and thus result in the observed n/e selectivity), it was unclear what structural difference between nNOS and eNOS resulted in these binding modes. Further complicating the interpretation of the eNOS structural data is the presence of both glycerol and acetate (crystallization buffer components) in all of the eNOS structures. While the glycerol is located peripherally relative to the inhibitor, the acetate (found in eNOS because of the alternate rotamer assumed by Arg252) abuts the perpendicular phenyl rings of the inhibitors and in several cases results in clearer electron density in the crystal structures, suggesting that the perpendicular binding modes may be stabilized by nonbonded contacts with the acetate and are thus likely a crystallographic artifact. By removing acetate from the cryo-soaking buffer, we were able to confirm that acetate is, indeed, the reason for some of these inhibitors to adopt a different binding mode in eNOS. This will be considered in more detail when the structures of 20 bound to eNOS and nNOS are discussed below.
To confirm this hypothesis further, the rat nNOS double mutant D597N/M336V was employed, where Asp597 and Met336 are mutated to, respectively, the corresponding asparagine and valine found in bovine eNOS. This enzyme has previously been used as an eNOS "surrogate" to elucidate the effects that amino acid differences have on inhibitor binding. 37, 38 While the active-site sequence resembles eNOS, the overall local environment and domain architecture still resemble wild-type rat nNOS; Arg481 (the equivalent of Arg252) is retained in the WT nNOS rotameric state, and acetate no longer binds. In the nNOS-D597N/M336V-9-structure ( Figure 6B ) the phenyl ether portion of 9 reverts to the coplanar binding mode observed in WT rat nNOS and not the perpendicular mode observed in the eNOS-9 structure, indicating that the upward position of the phenyl ring is likely stabilized or induced by the acetate. Nonetheless, a difference in the positioning of the methylamine tail in the nNOS-D597N/ M336V-9 structure ( Figure 6B ) could explain the observed selectivity for nNOS over eNOS. In the WT nNOS structure, the methylamine tail rotates away from bulky Met336, and the amino group faces toward the bridging water in the H 4 B site ( Figure 5B ). In the double mutant structure, the smaller Val336 (analogous to eNOS' Val106) allows for the amine to instead face toward the hydrophobic pocket, breaking the H 4 B site interaction. This is not the first reported case where subtle differences in Met/Val contacts have led to large effects on n/e selectivity 18, 39 and also serves as a cautionary note against overreliance on X-ray structures in interpretation of SAR data. As no acetate is used in the eNOS purification or assay, the 
Article observed eNOS selectivity for 9 was assumed to result from actual structural changes by comparing WT nNOS-9 and nNOS-D597N/M336V-9 structures. Assaying 9 against nNOS-D597N/M336V yielded a K i of 585 nM. This value is 4-fold higher than the WT nNOS K i , indicating that the Met-to-Val switch indeed disfavors binding to the double mutant. This value is also considerably lower than the eNOS K i value (25.3 μM), demonstrating that different amino acids are also not the full determinant of selectivity; subtle differences in sterics, electronics, or the local active site environment could also be responsible.
Although 6 and 7 are less potent than the shorter compounds (8−10), we reasoned that elongation of the alkyl chain by one methylene unit (to phenylpropyl, such as in 13 and 14) might either force the N-methyl groups toward the nNOS-specific hydrophobic pocket or place the basic amine near Asp597. Asn368 replaces Asp597 in eNOS (vide supra), and electrostatic or water-mediated contact with the latter residue has been previously implicated in high n/e selectivity. 26, 40 Disappointingly, this modification was ineffective: 13 and 14 are less potent than 6. Loss of activity upon extensive homologation was seen previously for 2-aminoquinoline compounds, 18 hypothesized to result from sterically disfavored, suboptimal, or partial interactions, or internal torsional strain. 

Article
We also synthesized para-substituted analogues 15 and 16 to investigate whether different ring substitution could improve potency or selectivity. Compound 15 has lower potency than meta-substituted analogue 9 (K i 283 nM vs 142 nM), and desmethyl compound 16 is slightly less potent than 15, indicating that the binding mode of these compounds must be different from the meta-substituted analogues. The nNOS-15 crystal structure ( Figure 7A ) indicates that the phenyl ring of 15 is oriented quite differently from that of 9. The alkylamine tail of 15, as a para-substituent, extends out farther with high flexibility. The methyl group makes possible contact with Met336, but the amine loses its effective H-bond interaction with the H 4 B site water. The flexible nature of the tail may allow it to make both the hydrophobic pocket and H 4 B site contacts transiently.
We also employed the secondary aniline (17 and 18) as a bioisosteric replacement for the ether oxygen. Crystal structures of the phenyl ether-linked compounds indicated a possible placement for the NH group between the heme propionates, where it could make another electrostatic or H-bonding interaction. Surprisingly, the potency for 17 was lower than that of 8, and the loss of additional potency upon demethylation (to 18) indicated that 17 and 18 do not bind like 8 and 9. The nNOS-17 structure ( Figure 7B ) reveals instead that the aminoquinoline and central aryl rings sit ∼120°r elative to each other in a "butterfly" position, reflecting the geometry required for the aniline nitrogen to interact with the nearby heme propionate. As a result, the aryl ring moves upward, and the dimethylamine H-bonds to Asn569. It is not evident from this structure as to why 17 should be a worse nNOS inhibitor than 8 (or why demethylation should further attenuate the activity), but both steric crowding around the Asn569-dimethylamine area (highly disordered in the crystal structure) and the lack of the inhibitor-Tyr706 pi-stacking interaction observed in 8 and 9 could play a role. Additionally, the eNOS-17 structure (see Figure S3 ) reveals a nearly identical binding mode to that assumed in the nNOS-17 structure, which could be consistent with the low selectivity of 17.
While the addition of a fluorine or α-methyl group to 9 (to give 19 or 22, respectively) was neutral (19) or a deleterious (22) modification with regard to both potency and selectivity (relative to 9, and thus were not investigated further or examined crystallographically), the replacement of the phenyl ring of 9 with pyridyl (21) resulted in a substantial increase in potency (K i 142 nM to 43 nM; more potent than 1 and 2). The nNOS-9 structure indicated the potential for the ring nitrogen to make an additional contact with Asn569, a prediction proven correct by the nNOS-21 structure ( Figure 8A ). Compound 21 assumes a well-defined, 9-like binding mode, where the external amine binds the H 4 B-site water and the pyridine ring simultaneously forms an edge-to-face pi-stacking interaction with Tyr706 and a polar contact with Asn569 (although at 3.7 Å, it is likely too far for a true H-bond). The high potency of 21 also highlights the absolute necessity of the external polar amine; compound 11, the unsubstituted 3-pyridine, binds nearly 17-fold weaker to nNOS than 21. While potent, 21 does not possess improved n/e selectivity relative to that of 9: this asparagine residue is conserved across all NOS isoforms, and interaction with the pyridine likely nonspecifically increases binding affinity to other isoforms, as manifested by the decreased K i values for eNOS and iNOS as well. 
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Article In contrast to para-fluoro compound 19, the para-chloro analogue 20 is much more potent than compound 9, with high isoform selectivity comparable to that of 1 and 2. The nNOS-20 structure ( Figure 8B ) shows that the phenyl ring is flexible, having two possible orientations in the two nNOS monomers, where the amine can either displace the H 4 B-site water or point toward the hydrophobic pocket by rotation of the phenyl ring, while the chlorine can make van der Waals contacts with Met336. The fluorine atom of 19 could be too small to make the latter contact, whereas the α-methyl group of 22 may be sterically disfavored in this region.
The eNOS-20 crystal structure (see Figure S4 ) also displays the "upward" binding mode and the stabilizing acetate ion. However, if acetate is removed from the cryo-soaking buffer, the phenyl ring of 20 no longer adopts the upward orientation ( Figure 8C ) but points toward the pocket bound by Val106, Leu107, and Tyr477, similar to the binding mode observed in the rat nNOS double mutant D597N/M336V-20 structure ( Figure 8D ). In addition, the positions of the phenyl ring and its two substituents (chlorine and methylamine) are better resolved than in the double mutant nNOS structure. The methylamine tail contacts Val106 but does not H-bond with the H 4 B or heme propionate A as observed in the wild type nNOS structure ( Figure 8B ). The chlorine makes no contact with Val106. As this binding mode is quite similar to that found in the double mutant structure ( Figure 8D ), we can confirm that acetate strongly influences the binding mode of inhibitors in eNOS structures and that the nNOS double mutant is indeed a good mimic of eNOS. In the nNOS double mutant-20 structure ( Figure 8D ), the Met-to-Val switch causes a significant change in binding mode: the phenyl ring has a single orientation rather than the two different ones observed in WT nNOS. The amine-H 4 B site interaction is broken; instead, the methylamine tail fits in the hydrophobic pocket, larger because of the smaller Val336 residue. In addition, there is a lack of van der Waals contact between 20's chlorine atom and Val336. Assaying 20 against nNOS D597N/M336V gave a K i value (863 nM) that is in between that of the WT nNOS (58 nM) and eNOS (12.5 μM) K i values, indicating, like for 9, that differences in amino acid sequences (such as Met to Val) do not fully account for the observed selectivity. Nonetheless, the double mutant nNOS/wild-type nNOS selectivity ratio (15) is higher than 9's (4) showing, as the crystal structure does, that the inhibitor-Met336 contact plays a greater role in n/e selectivity for 20 than it does for 9.
In addition to the good n/e selectivity, the majority of the phenyl ether compounds are also poor iNOS inhibitors (20− 150 μM). We had previously reported this incompatibility between iNOS and 2-aminoquinolines. 17 The high n/i selectivity was attributed in part to the mismatch between the smaller and more rigid heme-binding pocket of iNOS 41 and the bulky aminoquinoline, and in part to hydrophobic pocket contacts (as murine iNOS contains a polar residue, Asn115, in place of Leu337 of rat nNOS). Indeed, a bulky and hydrophobic group, such as chlorophenyl, may clash in the region of Asn115 and possibly lead to the high n/i selectivity observed for 20.
Several compounds of interest (6, 8, 9, 15, 17, 20 , and 21) were also assayed against purified human nNOS ( Table 2 ). The human nNOS active site differs from rat nNOS by one residue: Leu337 is replaced by His342. 42, 43 The peripheral pocket of human nNOS, therefore, prefers binding smaller and more hydrophilic fragments, as evident from the high rat nNOS/ human nNOS selectivity for the hydrophobic-tailed compounds 1 and 2. If the bound inhibitor cannot reach the Leu/His site, an identical binding mode should be found in both rat and human nNOS structures. 42 Aniline 17 is a typical example. In the human nNOS-17 structure (see Figure S5) , the "butterfly" binding mode is identical to that found in the rat nNOS-17 structure, and the bound inhibitor is far from the Leu/His site. Therefore, there should be little selectivity (r/h = 1.8 only) between these two nNOS enzymes. Most of the ether-linked compounds are poor human nNOS inhibitors (K i = 1−2 μM). The most potent human nNOS inhibitor, 20, is still selective for rat nNOS over human nNOS, even though it is approximately as potent as 1. The human nNOS-20 structure ( Figure 9A ) shows a consistent phenyl ring orientation where the dimethylamine makes an H-bond with the H 4 B site water; whereas in the rat nNOS-20 structure (Figure 8B ), the phenyl ring rotates and allows the dimethylamine to displace the H 4 B site water molecule in one orientation but extends the amine to the hydrophobic pocket in the other orientation (not shown). Apparently, the bulkier His342 in human nNOS influences the phenyl position of 20 differently than Leu337 in rat nNOS.
Pyridine analogue 21 strongly prefers to bind to rat nNOS (r/h = 11.8), although the binding mode shows almost no difference in the two nNOS structures ( Figure 9B for human). The only subtle difference observed in the structures is the side chain orientation of Tyr706 in rat compared to that of Tyr711 in human nNOS (because of the closer contacts from His342 in the human enzyme). A slight change in the edge-to-face pistacking interaction between the tyrosine and the inhibitor's pyridyl ring, however, would likely not fully account for the great difference in inhibitory potency.
Encouraged by the potency and selectivity of 20, this compound was tested in a Caco-2 assay (Table 3) , in which a compound's ability to cross a monolayer of cells (resembling the intestinal lumen) is measured. This assay can be used to approximate the permeability of the gut epithelium, and, to a lesser extent, the BBB. 44, 45 Compound 1, an orally bioavailable, brain-penetrant nNOS inhibitor, has good membrane permeability in the apical to basolateral (A → B) direction (a mean P app of 16.9 × 10 −6 cm s 
Article to efflux (B → A), < 3 is considered favorable]. Unfortunately, compound 20 is less cell-penetrant, has a slightly higher efflux ratio than 1, and has a lower A → B recovery value, potentially indicative of poor solubility or metabolic lability in these cells. Nonetheless, although suboptimal, some permeability is retained despite the drastic structural rearrangement.
Finally, 20 was screened by the PDSP. 19 In this assay, compounds are assayed against a panel of 45 pharmacologically relevant CNS targets via radioligand binding assays. We have classified off-target binding (Table 4 ) into four categories: concerning (K i < 100 nM, or < ∼2× nNOS K i value), moderate (100−300 nM, ∼2−5× nNOS K i value), weak (>300 nM, or > ∼5× nNOS K i value, typically ∼1 μM), and insignificant (<50% at 10 μM). For compound 2, a promiscuous scaffold with low therapeutic index, binding was considered concerning or moderate at 15/45 targets (mostly serotonin and histamine receptors), with 22/45 targets classified as weak, and 8/45 as insignificant. For compound 20, the concerning/moderate binding fraction has decreased to 6 targets, and the insignificant binding fraction has increased considerably, from 8/45 to 22/ 45, with the majority of the decrease coming from serotonin receptors. These results indicate that truncation and structural rearrangement, as observed for 4 and 5, are effective at reducing off-target CNS binding and could potentially translate to improved safety in vivo, making the phenyl ether-linked core an exciting scaffold for further optimization.
■ CONCLUSIONS
To summarize, we have developed a novel series of 2-aminoquinoline-based nNOS inhibitors, using the rationale that this particular "rearranged" scaffold could maintain or enhance the potency and isoform selectivity of our previous leads (1 and 2) while diminishing the off-target binding of these compounds. Assaying this new generation of inhibitors (containing an exterior polar amine and an interior hydrophobic portion linked to the aminoquinoline via a phenyl ether or aniline) against purified NOS enzymes indicated that 9, while having lower potency than 1 or 2, maintained the tripledigit isoform selectivity of the leads. X-ray crystallography (using rat nNOS and a rat nNOS double mutant) indicated that the n/e selectivity might arise from enhanced hydrophobic contacts between the tail of the inhibitor and the nNOS-specific hydrophobic pocket. Elongating the chain between the aryl ring and the amine, changing the ring substitution pattern, and replacing the phenyl ether linkage with an aniline failed to improve 9's potency and selectivity, but one compound (20) , chlorinated on the central aryl ring, was found to be a potent and selective inhibitor of both rat and human nNOS. Although lower than compound 1, 20 still displayed some cellular permeability in a Caco-2 assay despite the significant structural rearrangement. Most promisingly, when assayed against a panel of 45 relevant CNS targets and receptors in the PDSP, 20 showed diminished off-target interactions relative to those of 2 (a promiscuous binder) indicating that potent and selective compounds based on the inverted phenyl ether core may have the potential for improved safety in vivo.
■ EXPERIMENTAL SECTION
General Procedures. Anhydrous solvents (THF, CH 2 Cl 2 , MeOH, and DMF) were distilled prior to use. The remaining solvents, reactants, and reagents were purchased from commercial vendors and were used without further purification. Methanolic HCl (3 M, for ammonium salt formation and Boc-deprotection) was prepared fresh by the reaction of acetyl chloride and anhydrous MeOH at 0°C. Melting points were determined in capillary tubes using a Buchi a Off-target binding is classified into four categories: concerning (K i < 100 nM, or < ∼2× nNOS K i value), moderate (100−300 nM, ∼ 2−5× nNOS K i value), weak (>300 nM, or > ∼5× nNOS K i value, typically ∼1 μM), and insignificant (<50% bound at 10 μM), for a total of 45 receptors as assayed by the PDSP's "comprehensive screen". See ref 18 . The three concerning targets for compound 20 are the alpha-2C adrenergic receptor, histamine H2 receptor, and the serotonin transporter (SERT).
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Article melting point B-540 apparatus and are uncorrected.
1 H NMR spectra were recorded at 500 MHz, using a Bruker Avance III 500 (direct cryoprobe), and 13 C NMR spectra were obtained at 126 MHz using the same instrument. Low-resolution ESIMS was performed using a Bruker AmaZon SL Ion Trap mass spectrometer system. Highresolution mass spectral data were obtained at the Integrated Molecular Structure Education and Research Center (Northwestern University) on an Agilent 6210A TOF mass spectrometer in positive ion mode using electrospray ionization with an Agilent G1312A HPLC pump and an Agilent G1367B autoinjector. Data were processed using MassHunter software, version B.04.00. Flash column chromatography was performed using an Agilent 971-FP automated flash purification system with a Varian column station and SiliCycle cartridges (12−80 g). Analytical HPLC was performed using an Agilent Infinity 1260 HPLC system and injection volumes of 5−10 μL. A Phenomenex Luna 5 μm C-8(2) 100 Å column, 50 × 4.60 mm, was used for all HPLC experiments, using a 10 min gradient of 95% H 2 O/5% acetonitrile + 0.05% TFA to 95% acetonitrile/5% H 2 O + 0.05% TFA, at 1.5 mL/min. The purity of all final target compounds was found to be ≥95% by HPLC. 32 were prepared by known literature procedures, and their spectral data are consistent with those data reported for them. The preparations of phenols, anilines, and precursors 28−59 are discussed in the Supporting Information.
2-Amino-7-methylquinoline (24). Compound 23 (1.00 g, 5.63 mmol), DavePhos (0.051 g, 2 mol %), and Pd 2 (dba) 3 (0.051 g, ∼1 mol %) in a sealed tube or Biotage 20 mL microwave vial were diluted with anhydrous dioxane (6 mL), and LHMDS (1 M in THF, 12 mL, 12 mmol) was added slowly. The reaction was purged with argon for 5 min, sealed, and heated to 100°C for 20 h. The mixture was cooled and poured into aqueous HCl (1 M, 20 mL) and stirred for 10 min before EtOAc (20 mL) was added. The layers were separated, and the aqueous layer was extracted with 1 M HCl (3 × 50 mL); the aqueous phase was washed repeatedly with EtOAc (3 × 30 mL), and the combined organic phase was discarded. The aqueous phase was basified to pH 9 with NaOH and extracted with EtOAc (2 × 150 mL). The organic phase was washed with sat. aq. NaCl (100 mL), dried, and concentrated to yield the crude aminoquinoline as an off-white iridescent solid (0.900 g, 100% with minor impurities); analytical data for this compound are as previously described. 29 2-(Acetamido)-7-methylquinoline (25) . Compound 24 (3.02 g, 19.1 mmol) was diluted with anhydrous THF (100 mL), Nacetylimidazole (2.52 g, 23.0 mmol) was added, and the mixture was heated at reflux for 17 h. The mixture was cooled, concentrated, and the residue was diluted with EtOAc (200 mL) and washed with H 2 O (∼500 mL) and sat. aq. NaCl (100 mL). The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was dissolved in a minimal amount of hot EtOAc and precipitated with hexanes (∼200 mL) to yield 25 as a pale-tan iridescent solid (3.23 g, 85%) after washing with hexanes. Analytical data for this compound are consistent with those previously reported.
18,29
General Procedure for the Synthesis and Deprotection of Phenyl Ether-Linked Aminoquinolines. Sodium hydride (60% suspension in mineral oil, 1 equiv) was diluted with anhydrous DMF (1−2 mL) and cooled to 0°C under argon. A solution of the required phenol (1 equiv) in anhydrous DMF (1−2 mL) was added slowly to the suspension and stirred at 0°C for 10−30 min (typically ∼25 min), following which bromide 26 (1 equiv) was added as a solution in anhydrous DMF. The reaction mixture was stirred at 0°C for 40 min− 1 h (typically ∼50 min) and quenched at 0°C by addition of a 1:1 sat. aq. NaCl/H 2 O mixture (∼15 mL) or a sat. aq. NaHCO 3 solution. The mixture was extracted with EtOAc (usually 3 × 20 mL was sufficient; for tertiary amines, more exhaustive extraction was required), and the organic phase was washed with 5% aq. NaCl ((3−4) × 30−80 mL) and sat aq. NaCl (30−50 mL). The organic layer was dried over anhydrous sodium sulfate, concentrated, and purified by flash column chromatography (12 g SiO 2 cartridge), using gradients as described for individual compounds below. The resulting intermediate acetamides were not characterized or purified further but were diluted with anhydrous MeOH (5−10 mL), and anhydrous K 2 CO 3 (2−2.5 equiv) was added. The mixture was heated at reflux for 2−2.5, cooled, and concentrated. The resulting residue was partitioned between EtOAc and 1:1 H 2 O/sat. aq. NaCl, and the aqueous layer was extracted with EtOAc ((2−3) × 5−20 mL). The organic layers were washed with sat. aq. NaCl and dried over anhydrous sodium sulfate. Purification is detailed under subheadings for individual compounds. The free aminoquinoline was diluted in dry ether (or 10:1 ether/MeOH) and filtered to remove any particulate matter. To the filtered solution, methanolic HCl (3 M, 1.5 mL) was added, and the mixture was stirred either 5 min (when a Boc group was not present) or overnight (when a Boc group was present). The hydrochloride salts were isolated by filtration, and the final purification was performed as described below for individual compounds.
7-[(3-(2-(Dimethylamino)ethyl)phenoxy)methyl]quinolin-2-amine Dihydrochloride (6). This was prepared from 26 (0.150 g, 0.54 mmol) and phenol 29 (0.089 g, 0.54 mmol). Workup and purification by flash column chromatography, eluting with a gradient of 2% MeOH in EtOAc to 30% MeOH in EtOAc, afforded the intermediate acetamide 60 as a white semisolid (0.081 g, 41%) that was immediately deprotected using K 2 CO 3 (0.062 g, 0.446 mmol). After workup, the resulting gum was dissolved in minimal EtOAc, and hexanes were added to precipitate a white solid. This procedure was repeated twice, and the solid was diluted with 10% MeOH in ether (10 mL), filtered, and concentrated. The resulting residue was diluted in ether (∼10 mL) and treated with methanolic HCl for 5 min. Filtration afforded 6 (0.050 g, 57% from 64) as a cream-colored powder after washing with ether (3 × 2 mL): mp 115−120°C (softens), 240°C (dec). 1 181 g, 74%) , which was immediately deprotected using K 2 CO 3 (0.111g, 0.806 mmol). After workup, the resulting gum was triturated with hexanes and 1:1 ether/hexanes (5 mL each) and filtered to yield a white solid that was suspended in ether (8 mL) and treated with methanolic HCl (1.5 mL) for 20 h. Filtration afforded 7 (0.105 g, 69% from 61) as a chalky white solid after trituration with 10% MeOH in ether (3 × 1 mL): mp 211.5−213°C
. 1 091 g, 61%) , which was deprotected using K 2 CO 3 (0.089g, 0.65 mmol). After workup, the resulting syrup was triturated with 5:1 DCM/hexanes (5 mL) to yield a white solid. This was diluted in EtOAc (3 mL), filtered to remove particulates, and concentrated. The residue was diluted in MeOH (1 mL) and treated with methanolic HCl (1.5 mL). Ether was added to precipitate a gum that was washed with 5% MeOH in ether and ether (1 mL each) to yield 8 (0.063 g, 64% from 62) as a pale-yellow foam: mp 76°C (softens), 91−94°C (melts), 240°C (dec). 1 , which was deprotected using K 2 CO 3 (0.117 g, 0.844 mmol). After workup, the resulting residue was diluted in ether (5 mL), filtered to remove particulates, and treated with methanolic HCl (1.5 mL) for 20 h. Ether (3 mL) was added, and the precipitate was filtered to yield 9 as a white amorphous solid (0.102 g, 66% from 63) after trituration with 2:1 ether/MeOH (2 mL) and washing with ether (2 mL): mp 257−259°C. 1 121 g, 80%) , which was deprotected using K 2 CO 3 (0.079 g, 0.569 mmol). After workup, the resulting gum was triturated with 5:1 ether/hexanes and 2:1 hexanes/EtOAc (5 mL each) to yield the product as a white solid, which was diluted in MeOH, filtered to remove particulates, and concentrated. The residue was diluted with ether (8 mL) and treated with methanolic HCl (1.5 mL) for 20 h. The precipitate was filtered to yield 10 as a white powder (0.050 g, 50% from 64) after trituration with 15% MeOH in ether (2 × 2 mL) and 2:1 ether/MeOH (2 mL) and washing with ether (2 mL): mp 254− 255°C. -colored solid (0.068 g, 54%) , which was deprotected using K 2 CO 3 (0.064 g, 0.466 mmol). After workup, the resulting residue was triturated with DCM/hexanes (∼4 mL), and the pale-yellow iridescent solid was collected, dissolved in MeOH, filtered to remove particulates, and concentrated. The residue was resuspended in MeOH (1 mL), and methanolic HCl (1.5 mL) was added. After 5 min, the addition of ether (5 mL) precipitated 11 as an off-white solid (0.067 g, 88% from 74) after washing with ether (2 mL): mp 188°C (softens), 211−214°C (melts).
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1 H NMR (500 MHz; DMSO-d 6 ): δ14.35 (s, 1 H), 9.23 (br s, 1 H), 8.65 (s, 1 H) 7-((3-(Dimethylamino)phenoxy)methyl)quinolin-2-amine Dihydrochloride (12) . This was prepared from 26 (0.120 g, 0.43 mmol) and 3-(dimethylamino)phenol (0.041 g, 0.43 mmol). After workup, the resulting residue was purified by flash column chromatography, eluting with a gradient of 5% EtOAc in CH 2 Cl 2 to 25% EtOAc in CH 2 Cl 2 , to yield intermediate acetamide 65 (0.070 g, 49%) as a clear syrup, which was immediately deprotected using K 2 CO 3 (0.058 g, 0.42 mmol). After workup, the resulting oil was treated with methanolic HCl (4 mL), and ether (12 mL) was added to afford an off-white solid; an analytically pure sample for assay was prepared by preparative LC-MS, using the instrument described in the General Procedures section and a Phenomenex Luna 5 μm C8 (2) after filtering an EtOAc solution to remove particulates and reconcentrating. The intermediate acetamide was deprotected using K 2 CO 3 (0.077 g, 0.556 mmol). After workup, the resulting residue was diluted in CH 2 Cl 2 (1 mL) and precipitated with hexanes (5 mL) to yield the free aminoquinoline as a white solid, which was diluted with CH 2 Cl 2 , filtered again, and concentrated. The residue was diluted in ether (5 mL) and treated with methanolic HCl (1 mL) for 5 min. The mixture was then concentrated, and the residue was triturated with ether (2 × 5 mL), 10% MeOH in ether (4 × 5 mL), and EtOAc (5 mL), to yield 13 as an off-white foam (0.045 g, 40% from 66): mp 72− 75°C (softens), 260°C (dec). 123.8, 121.1, 120.3, 115.12, 115.01, 113.7, 112.3, 68.3, 56.1, 42.0 7-((3-(2-(Dimethylamino)ethoxy)phenoxy)methyl)quinolin-2-amine Dihydrochloride (14) . This was prepared from 26 (0.100 g, 0.36 mmol) and phenol 42 (0.065 g, 0.36 mmol). After workup, the resulting residue was purified by flash column chromatography, eluting with 50% EtOAc in hexanes + 5% Et 3 N, to yield intermediate acetamide 67 (0.050 g, 37%) as an opaque syrup, which was immediately deprotected using K 2 CO 3 (0.036 g, 0.26 mmol). After workup, the resulting oil was treated with methanolic HCl (3 M, 3 mL), and ether (9 mL) was added, affording an off-white solid; an analytically pure sample for assay was prepared by preparative LC-MS, using the instrument described in the General Procedures section and a Phenomenex Luna 5 μm C8 (2) 7-[(4-(Dimethylamino)methyl)phenoxy)methyl]quinolin-2-amine Dihydrochloride (15) . This was prepared from 26 (0.120 g, 0.43 mmol) and phenol 44 (0.065 g, 0.43 mmol). Workup and purification by flash column chromatography, eluting with a gradient of 3% MeOH in EtOAc to 20% MeOH in EtOAc, afforded crude acetamide 68 as a foamy pale-yellow semisolid (0.099 g, 66%), which was deprotected using K 2 CO 3 (0.078 g, 0.57 mmol). After workup, the resulting yellowish gum was triturated with 10% EtOAc in hexanes (10 mL), diluted with MeOH, filtered, and reconcentrated. The resulting residue was diluted with ether (5 mL) and treated with methanolic HCl (1 mL) for 5 min. Concentration afforded an off-white foamy solid; an analytically pure sample for assay was prepared by preparative LC-MS, using the instrument described in the General Procedures section and a Phenomenex Luna 5 μm C8(2) 100 Å, 150 × 21.2 mm preparative HPLC column, eluting with a gradient of 95% H 2 O + 0.1% formic acid/5% MeCN + 0.1% formic acid to 80% H 2 O + 0.1% formic acid 20% MeCN + 0.1% formic acid over 20 min. Evaporation of the desired mass fraction yielded a syrup that was suspended in MeOH (2 mL), filtered, concentrated, and treated with methanolic HCl (0.7 mL). Ether (5 mL) was added to precipitate 15, which was obtained as a white hygroscopic solid (0.022 g, 21% from 68) after washing with ether and drying: mp 251−253.5°C. 184 g, 78%) , which was deprotected using K 2 CO 3 (0.117 g, 0.844 mmol). After workup, the resulting residue was purified by flash column chromatography, eluting with a gradient of EtOAc to 2% MeOH in EtOAc, to yield a colorless foam. The free aminoquinoline was diluted with ether (7 mL) and treated with methanolic HCl (1.5 mL) for 18 h. The precipitate was filtered to yield 16 as a white chalky solid (0.131 g, 85% from 69) after washing with 20% MeOH in ether (5 mL) and drying: mp 283−285°C. (17) . Aldehyde 81 (0.080 g, 0.374 mmol) and aniline 48 (0.067 g, 0.449 mmol) were diluted in abs. EtOH (12 mL), and anhydrous Na 2 SO 4 (∼0.5 g) was added. The mixture was heated to 60°C for 1 h, glacial AcOH (8 μL) was added, and heating was continued for 22 h. The mixture was cooled to room temperature, and NaBH 4 (0.018 g, 0.486 mmol) was added, and after 20 min, the mixture was filtered. The filtrate was evaporated and partitioned between EtOAc and sat. aq. NaHCO 3 (20 mL each). The aqueous layer was extracted with EtOAc (2 × 30 mL), and the organic layer was washed with H 2 O and sat. aq. NaCl (20 mL each), dried over anhydrous sodium sulfate, and concentrated. The resulting residue was purified by flash column chromatography, eluting with a gradient of CH 2 Cl 2 to 25% MeOH in CH 2 Cl 2 , to yield the crude acetamide as a white solid (0.032 g, 25%) after trituration with 10% CH 2 Cl 2 in hexanes. The intermediate acetamide was deprotected using K 2 CO 3 (0.026 g, 0.188 mmol) and worked up using the general procedure; the obtained yellow gum was triturated with 10% EtOAc in hexanes and hexanes (3 mL each), diluted with 20% MeOH in ether (∼5 mL), and treated with methanolic HCl (0.5 mL) for 5 min. The precipitate was collected, diluted in MeOH (0.5 mL), and precipitated with ether (3 mL) to afford 17 (0.019 g, 12% from the acetamide) as a paleyellow powder: mp 219−221°C. 1 (18) . Bromide 26 (0.092 g, 0.330 mmol), aniline 50 (0.195 g, 0.826 mmol), and KI (0.006 g, 15 mol %) were combined in anhydrous MeCN (2.5 mL), sealed, and heated under microwave irradiation at 110°C for 20 min. The mixture was diluted with CH 2 Cl 2 (30 mL) and washed with sat. aq. NaHCO 3 (20 mL). The aqueous layer was extracted with CH 2 Cl 2 (20 mL), and the organic layers were washed with H 2 O and sat. aq. NaCl (30 mL), dried over anhydrous sodium sulfate, and concentrated. The residue was purified by flash column chromatography, eluting with a gradient of 5% EtOAc in CH 2 Cl 2 to 40% EtOAc in CH 2 Cl 2 , to yield intermediate acetamide 75 as a yellow foam (0.103 g, 72%), which was deprotected using K 2 CO 3 (0.065 g, 0.474 mmol) and worked up according to the general procedure. The resulting residue was purified by flash column chromatography, eluting with a gradient of EtOAc to 2% MeOH in EtOAc, to yield a pale-yellow foam. The free aminoquinoline was diluted with 30% MeOH in ether (11 mL) and was treated with methanolic HCl (1.5 mL) for 20 h. The precipitate was collected and precipitated from hot MeOH (0. 128 g, 79%) , which was immediately deprotected using K 2 CO 3 (0.078 g, 0.564 mmol). After workup, the resulting gum was triturated with hexanes (2 × 5 mL), diluted in 10% MeOH in ether (9 mL), and treated with methanolic HCl (1.5 mL) for 20 h. The precipitate was collected and precipitated 3 times from hot MeOH (0.5 mL) with ether (2.5 mL) to yield 19 as a white amorphous solid (0.053 g, 49% from 70): mp 293−294°C. 1 136 g, 81%) , which was deprotected using K 2 CO 3 (0.080 g, 0.578 mmol). After workup, the resulting gum was triturated with hexanes (2 × 5 mL), diluted in 10% MeOH in ether (9 mL), and treated with methanolic HCl (1.5 mL) for 20 h. The precipitate was collected and precipitated 4 times from hot MeOH (1 mL) with ether (3 mL) to yield 20 as a white amorphous solid (0.059 g, 51% from 71): mp 290−291.5°C (dec). 1 098 g, 63%) , which was deprotected using K 2 CO 3 (0.062 g, 0.449 mmol). After workup, the resulting gum was triturated with hexanes (2 × 5 mL), diluted in 10% MeOH in ether (9 mL), and treated with methanolic HCl (1.5 mL) for 20 h. The precipitate was collected and precipitated from hot MeOH (0.5 mL) with ether (2.5 mL) to yield 21 as a flocculent, cream-colored solid (0.056 g, 62% from 73): mp 224−226°C. 1 23 Compound 77 (2.2 g, 9.47 mmol) was diluted in DMF/glacial AcOH (1:1, 20 mL), and one portion of iron powder (1.85 g, 33.2 mmol, divided into two roughly equal amounts) was added in smaller portions. The mixture was heated to 100°C for 90 min, after which the second portion of iron was added in smaller portions. After a total of 2 h 50 min of heating, the mixture was cooled, concentrated to dryness, and the mixture was treated with sat. aq. NaHCO 3 (100 mL). This mixture was exhaustively extracted with EtOAc (total, 700 mL), and the organic phase was washed with sat. aq. NaCl (200 mL), dried over anhydrous sodium sulfate, and concentrated. The resulting yellow residue was diluted with EtOAc (10 mL) and heated until dissolution occurred. Hexanes (100 mL) were then added, and the mixture was sonicated vigorously until a precipitate formed. The precipitate was collected and washed with hexanes to yield 78 as a pale-yellow crystalline solid (1.59 g, 83% (60 mL) , and N-acetylimidazole (1.24 g, 11.2 mmol) and a catalytic amount (∼0.050 g) of DMAP were added. The mixture was heated at 100°C for 19 h, cooled, and concentrated, and the resulting residue was suspended in CH 2 Cl 2 (300 mL). The organic layer was washed with H 2 O (200 mL), and the aqueous layer was extracted with CH 2 Cl 2 (2 × 200 mL). The organic layers were washed with H 2 O (400 mL) and sat. aq. NaCl (300 mL), dried over anhydrous sodium sulfate, and concentrated. The residue was diluted in CH 2 Cl 2 (10 mL), and hexanes (150 mL) were added until a precipitate formed. This was collected and dried to yield 79 as a tan iridescent solid (2.08 g, 91%): mp 218−219.5°C. 1 , 100). N-(7-(Hydroxymethyl)quinolin-2-yl)acetamide (80). Compound 79 (0.732 g, 3.0 mmol) was diluted in anhydrous THF (10 mL) and cooled to −15°C. LiAlH 4 (1 M in THF, 4.5 mL, 4.5 mmol) was added dropwise over 5 min, and the mixture was stirred for 1 h. The reaction was quenched by the addition of EtOAc (10 mL) and sat. aq. sodium potassium tartrate solution (20 mL) and stirred until two layers formed. The layers were separated, and the aqueous layer was extracted with EtOAc (4 × 50 mL). The organic phase was washed with sat. aq. NH 4 Cl (50 mL), the aqueous phase was re-extracted with 20 mL of EtOAc following this wash, and the combined organic layers were washed with sat. aq. NaCl (50 mL), and dried over anhydrous sodium sulfate. Concentration afforded a white residue, which was precipitated from minimal EtOAc with hexanes to afford crude 80 as a white solid (0.433 g, 67%), which was used in the following step without further purification; 1 (25 mL) , and alcohol 80 (0.364 g, 1.71 mmol) was added in one portion. The mixture was stirred at room temperature for 70 min and then quenched by the addition of sat. aq. Na 2 S 2 O 3 (15 mL). After being stirred for 15 min, the layers were separated, and the aqueous layer was extracted with CH 2 Cl 2 (2 × 20 mL). The organic layers were washed with sat. aq. NaHCO 3 and sat. aq. NaCl (20 mL each). The organic layer was dried over anhydrous sodium sulfate and concentrated, and the residue was purified by flash column chromatography, eluting with a gradient of CH 2 Cl 2 to 40% EtOAc in CH 2 . Purified NOS Enzyme Assays. Rat and human nNOS, murine macrophage iNOS, bovine eNOS, and rat nNOS double mutant D597N/M336V were recombinant enzymes, expressed in E. coli and purified as previously reported. 49−51 To test for enzyme inhibition, the hemoglobin capture assay was used to measure nitric oxide production. The assay was performed at 37°C in HEPES buffer (100 mM, with 10% glycerol, pH 7.4) in the presence of 10 μM Larginine. Also included were 100 μM NADPH, 0.83 mM CaCl 2 , approximately 320 units/mL of calmodulin, 10 μM H 4 B, and human oxyhemoglobin (3 μM). For iNOS, CaCl 2 and calmodulin were omitted and replaced with HEPES buffer (as neither are required for activation of iNOS). The assay was performed in 96-well plates using a Synergy 4 BioTek hybrid reader, and the dispensing of NOS enzyme and hemoglobin were automated; after 30 s (maximum delay), NO production was read by monitoring the absorbance at 401 nm (resulting from the conversion of oxyhemoglobin to methemoglobin). Kinetic readouts were performed for 3 or 5 min. Each compound was assayed at least in duplicate, and seven to nine concentrations (500 μM−50 nM or 100 μM−10 nM for eNOS and iNOS; 50 μM to 5 nM for nNOS) were used to construct dose−response curves. IC 50 values were calculated by nonlinear regression using GraphPad Prism software, and K i values were obtained using the Cheng−Prusoff equation 52 [K i = IC 50 /(1 + [S]/K m )] with the following K m values: 1.3 μM (rat nNOS), 1.6 μM (human nNOS), 8.2 μM (murine macrophage iNOS), 1.7 μM (bovine eNOS), and 1.9 μM (rat nNOS D597N/M336V double mutant). 38 Inhibitor Complex Crystal Preparation. The preparations of rat nNOS (wild type or D597N/M336V double mutant), bovine eNOS, and human nNOS heme domains used for crystallographic studies were carried out using the procedures described previously. 42, 53 The rat nNOS heme domain (WT or double mutant, at 9 mg/mL containing 20 mM histidine) or the bovine eNOS heme domain (at 10 mg/mL containing 2 mM imidazole) were used for the sitting drop vapor diffusion crystallization setup under conditions previously reported. 54, 55 Human nNOS crystals were obtained with the triple K301R/R354A/G357D mutant heme domain sample at 10 mg/mL. By slightly modifying the original conditions 42 where the monoclinic C2 crystals grew, a new crystal form belonging to the P2 1 2 1 2 1 space group was obtained. 42 Fresh crystals (1−2 days old) were first passed stepwise through cryoprotectant solutions and then soaked with 10 mM inhibitor for 4−6 h at 4°C before being flash cooled with liquid nitrogen.
X-ray Diffraction Data Collection, Data Processing, and Structural Refinement. The cryogenic (100 K) X-ray diffraction data were collected remotely at the Stanford Synchrotron Radiation Lightsource (SSRL) or Advanced Light Source (ALS) through the data collection control software Blu-Ice 56 and a crystal mounting robot. When a Q315r CCD detector was used, 100−125°of data were typically collected with 0.5°per frame. If a Pilatus pixel array detector was used, 140−160°of fine-sliced data were collected with 0.2°per frame. Raw CCD data frames were indexed, integrated, and scaled using HKL2000, 57 but the pixel array data were processed with XDS 58 and scaled with Scala (or Aimless). 59 The binding of inhibitors was detected by initial difference Fourier maps calculated with REFMAC. 60 The inhibitor molecules were then modeled in COOT 61 and refined using REFMAC or PHENIX. 62 Disordering in portions of inhibitors bound in the NOS active sites was often observed, sometimes resulting in poor density quality. However, partial structural features usually could still be visible if the contour level of the σA weighted 2m|F o | − D|F c | map dropped to 0.5 σ, which afforded the building of reasonable models into the disordered regions. Water molecules were added in REFMAC and checked by COOT. The TLS 63 protocol was implemented in the final stage of refinements with each subunit as one TLS group. The omit F o − F c density maps were calculated by removing inhibitor coordinates from the input PDB file before running one more round of TLS refinement in REFMAC or in PHENIX (simulated annealing protocol with a 2000 K initial temperature). The resulting map coefficients DELFWT and PHDELWT were used to generate maps. The refined structures were validated in COOT before deposition in the RCSB protein data bank. The crystallographic data collection and structure refinement statistics are summarized in Table  S1 , with the PDB accession codes included.
Caco-2 Permeability Assay. Caco-2 monolayer assays were performed by Cyprotex US, LLC (Watertown, MA) using the following standard procedure: Caco-2 cells, grown in tissue culture flasks, were trypsinized, resuspended, and grown and differentiated in 96-well plates for 3 weeks; monolayer formation was determined by measuring the transport of Lucifer yellow, an impermeable dye. All assays were performed at a concentration of 10 μM for 2 h. For apical to basolateral (A → B) permeability, compounds were added on the apical side (A), with permeation determined at the receiving (basolateral, B) side, where the receiving buffer was removed for analysis by LC/MS/MS using an Agilent 6410 mass spectrometer (ESI, MRM mode) coupled with an Agilent 1200 HPLC, using propranolol as an analytical internal standard. Buffers used were 100 μM Lucifer yellow in transport buffer (1.98 g/L glucose in 10 mM HEPES, 1× Hank's Balanced Salt Solution, pH 6.5) (apical side) and transport buffer at pH 7.4 (basolateral side). Apparent permeability (P app ) is expressed using the following equation: P app = (dQ/dt)/C 0 A, where the numerator is the rate of permeation, C 0 is initial concentration, and A is the monolayer area (0.11 cm 2 ). For bidirectional permeability, the efflux ratio was defined as P app (B → A)/P app (A → B); high efflux ratio values (>3) indicate that a compound may be a substrate for P-gp or other active transport systems. 
